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The Wigler and Hicks group studies human cancer and 
genetic disorders from a population genomics perspective. 
The cancer effort focuses on breast and prostate cancer 
(the latter jointly with Lloyd Trotman) and involves col­
laborative clinical studies (with local, national, and inter­
national collaborators) to discover mutational patterns 
predicting treatment response and outcome. We also de­
velop methodology for single-cell genomic and RNA 
analyses to detea cancer cells in bodily fluids such as blood 
and urine. This last has major potential applications to the 
early detection of cancer and monitoring its recurrence 
and response to therapy during and after treatment. The 
single-cell analysis has also led to insights about the clonal 
evolution and heterogeneity of cancers (Navin et al. 2011). 
This work may lead to a better understanding of initia­
tion, progression, and metastasis and shed light on the 
stem cell hypothesis of cancer and host responses.
Our genetic efforts are largely focused on determining 
the role of new (de novo) mutation in pediatric disorders 
with a strong genetic contribution. We study autism as 
part of a large study of simplex families organized by the 
Simons Foundation (Fischbach and Lord 2010), as well 
as congenital heart disease with Dorothy Warburton of 
Columbia University and pediatric cancers with Ken 
Offit of Memorial Sloan-Kettering Cancer Center 
(MSKCC). In collaboration with Alea Mills, we helped 
create a mouse model for one of the most common ge­
netic abnormalities contributing to autism (Horev et al. 
2011). Recent work has confirmed and extended our 
previous observations on the role of de novo copy-num- 
ber variation (large-scale mutation) in autism (Levy et al. 
2011), with similar results in the other disorders. In a 
large-scale exome sequencing project in collaboration 
with Dick McCombie (at the Genome Center at CSHL) 
and the Genome Sequencing Center at Washington Uni­
versity in St. Louis, we have proven the role of small-scale 
de novo mutations that disrupt genes in autism (Iossifov 
et al. 2012). Overall, our results succeed in confirming 
our previous genetic models for autism incidence and 
identify strong candidate mutational targets, from which 
biological models of autism can be made and tested.
Breaking with tradition, the remainder of this report 
contains two position statements on the direction in 
which we are taking our science, and why.
Applications of Single-Cell Analysis 
to Biological and Medical Problems
For several years, we have explored methods for gathering 
and analyzing nucleic acid sequences from single cells. 
There are at least five broad areas in which single-cell 
methods can be applied: (1) cancer, (2) neurobiology, (3) 
disorders of stem cell renewal, (4) detailed dissection of 
cell-state transitions, and (5) genome assembly. We are 
working on each. All of these applications require im­
provements in the gathering of single-cell data, both its 
quality and cost, and developing new processing algo­
rithms. Some of the mathematical challenges are new. To 
improve data generation, we make use of DNA barcod- 
ing to facilitate massively parallel sample processing, in­
crease the uniformity of data quality, and reduce costs.
The applications of single-cell analysis in cancer are 
nearly endless. Single-cell genome analysis can be used for 
detecting cancer cells in samples such as blood or urine 
obtained by noninvasive or minimally invasive proce­
dures. A more thorough analysis of standard biopsy ma­
terial, such as needle biopsies, can be achieved by 
single-cell genome profiling, revealing details of cancer 
heterogeneity, subpopulation structure, host reaction, and 
the presence of cancer cells in surgical margins and lymph 
nodes. Through single-cell RNA expression, the host re­
sponse at the sites of cancer growth can be monitored: the 
presence of capillary endothelium, immunocytes of all 
types, and reactive stroma. The identity of soluble factors 
to which these cells are responding may be inferred by 
observing their response signatures. By means of statisti­
cal methods correlating clinical outcomes with single-cell 
observation, we shall be able to improve detection, prog­
nosis, therapeutic choice, and monitoring response to 
therapy. The most transformative application would be a 
blood test for early detection of cancer onset, where the
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DNA analysis provides evidence for the presence of can­
cer cells and disease stage, and the RNA analysis indicates 
the cancers tissue origin and subtype. Both together can 
aid in prognosis and choice of therapeutic intervention. 
Finally, many fundamental questions of cancer biology 
can be addressed by single-cell analysis. Among these: 
How do cancer populations evolve? Is there in fact a stem 
cell population that is genetically distinct from the ma­
jority of the tumor population? From what cell or com­
bination of cells do metastases arise? To what extent and 
through what processes do cancer cells cooperate?
Single-cell expression analysis can also be used to de­
velop a deeper understanding of neural and nonneural 
subtypes in the nervous system (brain, chord, and gut) 
where tissue heterogeneity obscures bulk analysis. The 
result can be a better modeling of neuronal networks 
through identification of neuronal subtypes and a bet­
ter understanding of the response of neuronal cells to 
stimuli. The role of somatic mutation in nervous system 
disease can be explored. Finally, these methods can help 
refine our knowledge of the fates of pluripotent stem 
cells induced to differentiate into neuronal cells. If suc­
cessful, we could explore the functional consequences of 
candidate gene mutations.
The identity of stem cells and the role of aberrant 
stem cells in medical disorders are still highly unexplored. 
By an iterative process coupling cell separation and re­
generative assays, single-cell RNA analysis can help iden­
tify which cells in a tissue or in distant tissues are in fact 
the cells with regenerative capacity. Several medical dis­
orders, particularly those of aging, may be the result of 
somatic mutation in stem cells causing the replacement 
of critical cell types over time with dysfunctional versions. 
The types of disorders that might be caused by this 
mechanism include a wide variety of neurodegenerative 
conditions (e.g., Alzheimer’s), disorders of autoimmu­
nity (e.g., lupus), cardiomyopathies, and a variety of cu­
taneous (e.g., psoriasis) and connective tissue (e.g., 
scleroderma) diseases. The mechanisms underlying these 
disease processes might become apparent by combining 
DNA and RNA analysis of single cells, looking for aber­
rant genomes or expression patterns in stem cells. The 
latter may be identified at the single-cell level in complex 
organs, thereby overcoming the problems that beset the 
analysis of mixed-cell populations.
Examples of cell-state transitions abound in all living 
systems: the progression through the cell cycle, response 
to nutrient opportunity, differentiation, responses to 
growth factors and other signaling molecules, and even 
responses to contact with other cells. Often, these tran­
sitions involve a causal sequence of changes in the ex­
pressive state of the cell, the proteins and RNAs that they 
make. Because these changes typically occur in cell pop­
ulations that are not in temporal synchrony, the study of 
the sequence of changes often cannot be determined with 
precision. Single-cell analysis offers one way around this 
problem, as each cell represents a snapshot in time at the 
point when it is destroyed and converted to an ensemble 
of macromolecules. In principle, the overall series of 
changes can then be assembled into a coherent whole 
provided that (1) there is some overlapping signature in 
the macromolecular composition between time-adjacent 
states and (2) the temporal series is relatively similar from 
cell to cell.
We can make sequence libraries from a fraction of a 
cell genome. Genome analysis itself can be improved 
by doing this. If the DNA of a cell is diluted sufficiendy 
into isolated “packets,” any contiguous region we se­
quence from a given packet is likely to represent only 
one of the two parental haplotypes. If the DNA is not 
broken into small pieces during dilution, but diluted 
in large blocks—even if we subsequently break the 
DNA into small pieces when we make libraries—we 
can reassemble the short-read sequences into large hap- 
lotype blocks. The result, if conducted efficiendy using 
many cells as a starting point, would ultimately be a 
haplotypic assembly of the genome of any organism at 
roughly the cost of sequencing the entire organism in 
the conventional manner. As a practical matter, this 
converts the most efficient sequencing apparatus cur- 
rendy available, which is a short-read apparatus, into a 
long-read single-molecule apparatus.
Genetic Models of Autism
A large proportion of our lab works on autism genetics. 
The purpose of these notes is to give some scientific per­
spective to what the group has achieved and the future 
direction it will take. The rewards of studying autism 
from a genetic point of view are great. The disorder affects 
some of the most profoundly human traits. A complete 
analysis may reveal new sources of phenotypic variation. 
A good set of targets provides guides to therapies. And 
there are unmet needs for early detection and counseling 
families and individuals coping with the condition.
It was evident to some by as early as the mid 1980s 
that autism was likely to be a disorder caused by new 
mutation. The disorder was variable, hinting at multi­
ple underlying causes; the incidence was high; the her­
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itable component was appreciable but low; but the con­
cordance in identical twins was higher than in any other 
cognitive or behavioral impairment. Human geneticists 
had failed repeatedly to produce evidence of heritable 
underlying events, except in the limited cases of X- 
linked disease. In both of these cases, Fragile-X syn­
drome (FXS) and Rett syndrome, new or recent de 
novo mutations were clearly the root cause. Geneticists 
using transmission genetics would explain their failure 
under the rubric of a “complex” disorder, caused by 
subde interactions of multiple genes that would there­
fore be hard to crack. But what we knew in fact pointed 
to the existence of singular events of strong penetrance. 
Cytologic analysis had showed that many rare large- 
scale chromosomal events could result in developmen­
tal anomalies. Cytology could only scratch the surface 
of the richness of the consequences of new mutation.
In the early 2000s, methods for examining copy- 
number variation (CNV) developed in our lab (Lucito 
et al. 2003) became very powerful when combined with 
the data of the human genome sequence assembly 
(Healy et al. 2003). This led to the discovery of wide­
spread CNV in the human gene pool (Sebat et al. 
2004) and the hope that we could demonstrate autism 
was associated with new mutations likely to disrupt the 
dosage of functioning genes. Supported by the Simons 
Foundation, we succeeded in showing this (Sebat et al. 
2007), and our work fed the acceptance of the idea that 
disorders associated with drastically reduced fecundity 
would be often caused by new mutation through the 
action of gene dosage effects. Altering the functional 
dosage of certain genes, whether by duplication, dele­
tion, or disruption, would manifest upon transmission 
as dominant traits, and we sought evidence for this in 
the AGRE data of multiplex families. We found the ev­
idence (Zhao et al. 2007), namely, that boys born to 
parents with two previous offspring with autism spec­
trum disorder (ASD) had a 50% chance of being on 
the spectrum. These observations were confirmed in in­
dependent studies by ourselves and others.
Mathematical modeling of the family risk function 
using the AGRE data, and data from other sources, led 
to several predictions (Zhao et al. 2007). Up to half of 
autism might be explained by new mutation, and a 
large part of the remainder would be due to transmis­
sion of strongly penetrant variants carried by asympto­
matic parents. We speculated that most often the carrier 
parent would be the mother.
Subsequent work has focused on defining the list of 
autism target genes and developing a more quantitative
genetic model. We seek a list of target genes in the expec­
tation that such a list would provide medical geneticists 
with improved tools for diagnosis, especially early diag­
nosis, and also yield insights into physiologic mechanisms 
and thus ideas for intervention. Our most recent studies 
of autism were based on the Simons Simplex Collection, 
an unparalleled sample set, and are published in Neuron 
(Gilman et al. 2011; Iossifov et al. 2012; Levy et al. 2011). 
These papers provide a leap forward in assembling the list 
of gene targets (Gilman et al. 2011), validated the role of 
de novo CNV in autism (Levy et al. 2011), and provided 
evidence of a roughly equal role of transmission of rare 
CNV. Levy et al. (2011) provided evidence that the 
autism candidate loci contained a functionally convergent 
network of genes, and they extracted a list of the most 
likely autism candidate loci from the CNV data. Iossifov 
compared sequence data within families to find com­
pelling evidence that de novo mutations which disrupt 
genes contribute to autism. Many of the findings of Ios­
sifov are found in three smaller studies published essen­
tially concurrendy (Neale et al. 2012; O’Roak et al. 2012; 
Sanders et al. 2012). Recurrence analysis confirmed pre­
vious estimates that there are on the order of 200-800 
(most likely, 350-400) dosage-sensitive genes that when 
disrupted can contribute significandy to autism. Most sig- 
nificandy, the list of genes showed a strong overlap with 
genes that encode proteins whose translation may be 
under the control of FMRP, the product of the gene re­
sponsible for fragile-X syndrome (FXS). Nearly half of 
autism dosage-sensitive genes may be so controlled. 
FMRP is one of the central regulators of synaptic plastic­
ity, the physiologic mechanism underlying the response of 
neural networks to repetitive stimuli.
In addition to producing an extensive list of well- 
vetted autism gene targets, we have focused on obtain­
ing a better, more detailed quantitative genetic model 
for autism incidence. What answers would such a 
model provide, and why would they be useful? A de­
tailed quantitative model would determine with greater 
precision the number of dosage-sensitive gene targets 
and determine more precisely the overall role of these in 
incidence. Without such information, it will be hard to 
know how much of causation we are missing, and 
whether we need to consider extragenic mechanisms to 
explain phenotypic variation. Without such a model, 
we would be unaware of whether we were dealing com­
petently with the problem. An adequate model would 
explain the role of gender bias in transmission, and 
whether certain targets are gender-specific. Properly un­
derstood, gender bias might guide thinking about ther-
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apy. At the present time, there are gaps in the evidence 
supporting any model or mixture of models. Filling 
those gaps either with further evidence or by correct­
ing the models will be valuable contributions to our un­
derstandings of genetics and cognition.
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